EASD 2025 Preview: Key Diabetes Highlihts to Watch

EASD 2025 at a glance

In the lead-up to EASD 2025, LucidQuest spotlights the key themes shaping diabetes research, metabolic science, digital therapeutics, and AI-supported diabetes care.

📅 Build your schedule around the topics that interest you.

📥 Download the EASD 2025_Preview_by_LucidQuest

Dive deeper

Key Topics From EASD 2025 Scientific Presentations

Incretin Era 2.0 💊

• Oral, dual, long-acting GLP-1/GIP/amylin agents drive glycemic, weight, and cardiometabolic gains.

Risk-Tailored Benefits 🎯

• Oral semaglutide’s CV effect expected to rise at higher HbA1c; GLP-1s aid complex obesity.

Next-Gen & Duals 🧬

• Ecnoglutide, amycretin, HRS9531 project robust efficacy with improved tolerability.

Dosing & Delivery 📦

• Bi-weekly GLP-1s, oral small-molecule GLP-1RAs, and new amylin analogues expand options.

Obesity Paradigm ⚖️

• Cagrilintide/semaglutide and dual incretins sustain loss; ultra-long GLP-1s/multi-agonists extend durability.

T1D & Tech 🤰

• Insulin resistance flagged as CV risk; FLO23011 and tirzepatide under study; AID systems improve control—including in pregnancy.

T2D Pharmacology 💉

• New orals/injectables (e.g., imeglimin, enavogliflozin) cut HbA1c; iGlarLixi > IDegAsp; early quadruple therapy excels.

GDM & Postpartum 👶

• WHO-2013 raises treatment load without LGA benefit; rt-CGM lowers LGA; scalable postpartum tools emerge.

CV-Renal-Metabolic ❤️

• Icosapent ethyl lowers events across IR; semaglutide may reduce limb events in PAD; SGLT2i lessen anti-VEGF need in mild DME; CPAP cuts mortality in T2D-OSA.

Precision & Comorbidities 🧪

• TyG/mtDNAcn refine risk; semaglutide benefits MASH/PAD; monitor renal signals with anti-VEGF.

Devices & Digital 📲

• Hybrid closed-loop, smart MDI, and non-invasive Glucowear push personalized, real-world control.

Artificial Intelligence and Machine Learning at EASD 2025

Early Charcot Dx 🦶

• CHAID models flag erythema/edema/temperature clusters.

CGM → CV Risk 📈

• AI on cWT-CGM predicts ACS (~0.94 accuracy/AUC).

Better eGFR 🧮

• RenoTrue ANN outperforms CKD-EPI (higher ICC, lower bias).

Genomic T2D Onset 🧬

• RF/SVM with key SNPs reach ~90% AUC (≤55 yrs).

No-Show Forecasts 📆

• AUC ~0.78 enables proactive outreach.

Insulin Intelligence 🤖

• AI matches clinicians (>90%) for patterns/meals/bolus.

Adherence Personas 🧩

• LightGBM+SHAP (AUROC ~0.86) surfaces nine profiles.

DR Motivation 👁️

• AI retinal visuals drop HbA1c (≈8.9% → 8.1%)